Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor

• 
  

  Search all BMC articles
  Allergy, Asthma & Clinical Immunology
• Research
• Open Access

• Lundy McKibbin, 
• Colin Barber, 
• Chrystyna Kalicinsky & 
• Richard Warrington 

Allergy, Asthma & Clinical Immunology volume 15, Article number: 66 (2019)

Abstract

Background

Hereditary angioedema with normal C1 inhibitor (HAE-nC1 INH) is a rare, underappreciated condition characterized by recurrent subcutaneous angioedema. The underlying pathophysiology and diagnostic criteria continues to evolve. There is a significant overlap between HAE-nC1 INH and idiopathic nonhistaminergic angioedema, ultimately this may be found to be the same condition. Characterization of cohorts suspected to have either of these conditions is warranted to help refine diagnosis, pathophysiology, and treatment response.

Methods

Review of the Manitoba cohort of patients
with HAE-nC1 INH: inclusion criteria

A retrospective chart review of 418 patients diagnosed with angioedema was conducted.

The safety and tolerability profile of bilastine for chronic urticaria in children

• Clinical and Translational Allergy
• Review
• Open Access

• Nikolaos G. Papadopoulos & 
• Torsten Zuberbier 

Clinical and Translational Allergy volume 9, Article number: 55 (2019) 

• details

Abstract

Background

Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child’s daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition.

Eliciting dose is associated with tolerance development in peanut and cow’s milk allergic children

• Letter to the Editor
• Open Access

Clinical and Translational Allergy

• C. Nitsche, 
• C. D. Westerlaken-van Ginkel, 
• B. J. Kollen, 
• A. B. Sprikkelman, 
• G. H. Koppelman & 
• A. E. J. Dubois 

Clinical and Translational Allergy volume 9, Article number: 58 (2019) 

• details

Abstract

Background

Kaplan-Meier survival curve in peanut, cow’s milk and hen’s egg allergic children

Tolerance development rates differ between food allergies. Almost all previous studies have not used the gold standard method, the double-blind, placebo-controlled food challenge (DBPCFC), which may affect the reported prevalence rates. Little is known about the association of the eliciting dose (ED) obtained during the initial DBPCFC with later tolerance development.

Helsinki by nature: The Nature Step to Respiratory Health

• Review
• Open Access

Clinical and Translational Allergy

• Tari Haahtela, 
• Leena von Hertzen, 
• […]
• Nils E. Billo 

Clinical and Translational Allergy volume 9, Article number: 57 (2019) 

Abstract

Background

Several non-communicable diseases have been suggested
to share the same underlying risk factors such as microbial imbalance,
 long-term immune dysfunction and low-grade inflammation

The Nature Step to Respiratory Health was the overarching theme of the 12th General Meeting of the Global Alliance against Chronic Respiratory Diseases (GARD) in Helsinki, August 2018. New approaches are needed to improve respiratory health and reduce premature mortality of chronic diseases by 30% till 2030 (UN Sustainable Development Goals, SDGs). Planetary health is defined as the health of human civilization and the state of the natural systems on which it depends. Planetary health and human health are interconnected, and both need to be considered by individuals and governments while addressing several SDGs.

The association between caesarean section and childhood asthma: an updated systematic review and meta-analysis

Allergy, Asthma & Clinical Immunology

Behzad Darabi, 

Shoboo Rahmati, 

Mohammad Reza HafeziAhmadi, 

Gholamreza Badfar & 

Milad Azami 

Allergy, Asthma & Clinical Immunology volume 15, Article number: 62 (2019) 

• details

Abstract

Background

Investigating the association between caesarean section (SC) and childhood asthma has shown contradictory results in different studies. The present study was conducted to determine the association between SC and childhood asthma.

Material and method

The present study was conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. All the steps of the study were conducted independently by two reviewers from the inception until February 1, 2019.

The safety and tolerability profile of bilastine for chronic urticaria in children

• Review
• Open Access
• Clinical and Translational Allergy

• Nikolaos G. Papadopoulos & 
• Torsten Zuberbier 

Clinical and Translational Allergy volume 9, Article number: 55 (2019) 

Abstract

Background

Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child’s daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition.

Clinical Reflections®: Reflecting on Errors and Missed Opportunities in Chronic Urticaria

FORMAT

Roundtable

TIME TO COMPLETE

45 minutes

RELEASED

February 1, 2019

EXPIRES

January 31, 2020

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

START ACTIVITY

MAXIMUM CREDITS

0.75 / AMA PRA Category 1 Credit(s)TM

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

Key Points

Question  Does the oral Janus kinase 1 selective inhibitor abrocitinib improve atopic dermatitis signs and symptoms in adults with moderate to severe atopic dermatitis at doses that are well tolerated?

Findings  In this randomized, double-blinded, phase 2b clinical trial including 267 participants, the proportion of patients achieving substantial improvement from baseline was significantly greater for those receiving 200 mg and 100 mg of abrocitinib compared with placebo. Dose-related decreases in platelet count were observed for all doses greater than 10 mg, but platelet values trended upward toward baseline after the maximum decrease at week 4 and despite ongoing treatment with abrocitinib; most adverse events were mild and considered unrelated to treatment.

SABA overuse: Understanding the reasons for poor asthma control

Prof. John Haughney

Speaker

Clinical Director of the NHS Clinical Research Facilities, Glasgow

Dr John Haughney is a Clinical Director in clinical R&D and the Clinical Research Facilities in NHS Greater Glasgow & Clyde, Scotland, a part-time general practitioner and hospital respiratory specialist. He holds Fellowships from both the Royal College of General Practitioners and the Royal College of Physicians of Edinburgh.

John is a past-president of the International Primary Care Respiratory Group and a former Chair of the GPIAG (PCRS (UK)). He holds honorary academic positions at both the University of Glasgow and the University of Aberdeen and travels extensively teaching and learning about airways disease.

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

• Research article
• Open Access
• Open Peer Review

BMC Pulmonary Medicine

• Takanori Numata, 
• Katsutoshi Nakayama, 
• Hirofumi Utsumi, 
• Kenji Kobayashi, 
• Haruhiko Yanagisawa, 
• Mitsuo Hashimoto, 
• Shunsuke Minagawa, 
• Takeo Ishikawa, 
• Hiromichi Hara, 
• Jun Araya & 
• Kazuyoshi Kuwano 

BMC Pulmonary Medicine volume 19, Article number: 176 (2019) | 

Abstract

Background

Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors of the response to mepolizumab other than blood eosinophil count are unclear in clinical practice.

Risk factors for severe systemic sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients

• Clinical and Translational Allergy Research Open Access

• Danielle Fehr, 
• Sara Micaletto, 
• Thomas Moehr & 
• Peter Schmid-Grendelmeier 

Clinical and Translational Allergy volume 9, Article number: 54 (2019) | 

Abstract

Frequency of grades according to each insect

Background

Hymenoptera stings are a major cause of anaphylaxis. Various risk factors are discussed in literature. This study aims to investigate potential risk factors for severe sting reactions in wasp (Vespula spp.) and honeybee (Apis mellifera) venom allergic patients and analyses the correlation between diagnostic test results and the severity of the allergic reaction.

Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis

• Clinical and Translational Allergy
• Research
• Open Access
• 
  

• Joaquim Mullol, 
• Iñaki Izquierdo, 
• Kimihiro Okubo, 
• Giorgio Walter Canonica, 
• Jean Bousquet & 
• Antonio Valero 

Clinical and Translational Allergy volume 9, Article number: 50 (2019) 

Abstract

Background

Different clinical trials showed the superior efficacy of rupatadine compared to placebo at improving seasonal allergic rhinitis (SAR) symptoms, but no study has assessed if the response promoted is clinically meaningful.

Clinical Utility Of The Exhaled Nitric Oxide (NO) Measurement With Portable Devices In The Management Of Allergic Airway Inflammation And Asthma

Journal of Asthma and Allergy

Volume 2019:12 Pages 331—341

DOI https://doi.org/10.2147/JAA.S190489

Sy Duong-Quy<sup>1,2

1</sup>Department of Respiratory Diseases, Medical and Biological Research Centre, Lam Dong Medical College, Dalat City, Lam Dong Province, Vietnam; ²Department of Immuno-Allergology, Penn State Medical College, Hershey, PA, USA

Abstract: Nitric oxide (NO) is a potential bioactive gas produced continuously and constantly in the airways of healthy subjects. In allergic airway inflammation, the level of exhaled NO is usually increased and mediated by inducible nitric oxide synthase (iNOS) enzyme presenting in the epithelium and different inflammatory cells. The measurement of NO concentration in the airway is possible with portable devices which use an electroluminescence technique. In subjects with upper airway with allergic inflammation such as in allergic rhinitis, the measurement of nasal NO (nNO) may help to diagnose and manage the disease. In the lower airway, increased fractional exhaled NO (FENO) reflects directly the inflammatory process that occurs in the airways that are typically seen in asthma.

Origin of nasal NO and technique of nNO measurement.
Exhaled NO is produced from the epithelial cells, eosinophils,
 mast cells, and other cells under the activity of iNOS
 during contact with allergens. The measurement of nNO
is done by introducing the sampling catheter to the nasal
cavity via the nostril to aspirate the internal air stream. 

It has been shown that there is a strong correlation between FENO levels and increased activity of airway inflammation mediated by immuno-allergic cells and mediators. Thus, FENO has higher specificity and sensitivity than other methods in diagnosing the severity of inflammation in asthmatic patients. Moreover, the correlation between increased FENO levels and a high risk of bronchial hyperresponsiveness has also been demonstrated. FENO is also a relevant biomarker to evaluate asthma status due to the change of its values occurring earlier than clinical manifestations and spirometry parameters. In addition, the measurement of FENO with portable devices helps to support the diagnosis of asthma, to follow-up the control of asthma and to personalize asthmatic patients for target treatment with biologic therapy. Therefore, measuring FENO with portable devices in the diagnosis and treatment of allergic airway inflammation, especially in asthma, is one of the most essential applications of NO biomarkers in exhaled breath.

Download Article [PDF]

Myths, facts and controversies in the diagnosis and management of anaphylaxis

Review

Katherine Anagnostou, Paul J Turner

Abstract

Anaphylaxis is a serious systemic allergic reaction that is rapid in onset and may cause death. Despite numerous national and international guidelines and consensus statements, common misconceptions still persist in terms of diagnosis and appropriate management, both among healthcare professionals and patient/carers. We address some of these misconceptions and highlight the optimal approach for patients who experience potentially life-threatening allergic reactions.

PDF